ALK EML4::ALK C1156Y

CI-VAR-00005086Explore in graph →CIViC 6

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma2
ALK EML4::ALK C1156Y	Crizotinib	Predictive	C	Supports Resistance	3	rejected	EID8839 A 28 year-old patient with non-small cell lung cancer was found to harbor the EML4-ALK fusion using reverse transcription PCR. Treatment with 250mg crizotinib twice daily resulted in rapid improvement… (full text at CIViC) PMID 20979473 · Choi et al., 2010 · Open in CIViC	civic
ALK EML4::ALK C1156Y	Crizotinib	Predictive	D	Supports Resistance	—	rejected	EID4045 In an in vitro study, a Ba/F3 cell line expressing EML4-ALK fusion (a known sensitizing alteration to crizotinib) and an ALK C1156Y co-mutation demonstrated resistance to crizotinib treatment compared… (full text at CIViC) PMID 20979473 · Choi et al., 2010 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.